UCB:EBR
UCB SA
204,60 €
arrow_downward
-0,68%(-1,40) 1K
16-okt, 17:37:21 (GMT+2) · EUR
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoUCB tikeri uchun statistika yaratilmoqda...
Ochish
204,50 €
Yuqori
205,10 €
Past
201,30 €
Bozor kapitali
39,39Â mlrd
Oʻrtacha hajm
248,57Â ming
Hajmi
324,45Â ming
Dividend
0,50%
Choraklik dividendlar
0,25 €
Eks-dividend sanasi
4-may, 2026
P/E koeffitsiyenti
18,09
52 haftalik eng yuqori
289,50 €
52 haftalik eng past
197,45 €
Aksiya boʻyicha daromad
11,31 €
Muomaladagi aksiyalar
194,51Â mln
Xodimlar soni
9Â ming
Ochish
204,50 €
Yuqori
205,10 €
Past
201,30 €
Bozor kapitali
39,39Â mlrd
Oʻrtacha hajm
248,57Â ming
Hajmi
324,45Â ming
Dividend
0,50%
Choraklik dividendlar
0,25 €
Eks-dividend sanasi
4-may, 2026
P/E koeffitsiyenti
18,09
52 haftalik eng yuqori
289,50 €
52 haftalik eng past
197,45 €
Aksiya boʻyicha daromad
11,31 €
Muomaladagi aksiyalar
194,51Â mln
Xodimlar soni
9Â ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
ad-hoc-news.de
·
1 kun oldin
UCB launches Wear It Out: what it means for UCB stock
Profil
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
UCB SA haqida
CEOJean-Christophe Tellier
Xodimlar soni9Â ming
Asos solingan18-yan, 1928
Bosh ofislar-
Sektor-
Veb-saytucb.com